Literature DB >> 172259

Facilitation of adrenergic transmission by locally generated angiotensin II in rat mesenteric arteries.

K U Malik, A Nasjletti.   

Abstract

When studied on isolated rat mesenteric arteries perfused with Tyrode's solution, angiotensin I and angiotensin II (1 ng/ml), a synthetic tetradecapeptide renin substrate, and a purified hog renin substance (50-100 ng/ml) potentiated vasoconstrictor responses to sympathetic nerve stimulation and to injected norepinephrine without altering basal pressure. These agents produced a greater augmentation of the vasoconstrictor responses to nerve stimulation than to injected norepinephrine. The potentiation of vasoconstrictor responses to sympathetic nerve stimulation and injected norepinephrine which was elicited by renin substrate and angiotensin I was abolished by an inhibitor of angiotensin I-converting enzyme, SQ 20,881, and by an angiotensin II receptor antagonist, [Sar1-Ile8]angiotensin II. In contrast, the potentiating effect of angiotensin II was blocked only by the latter compound. We conclude that utilization of renin substrate within the vascular wall by renin or renin-like enzymes results in the formation of angiotensin I, which is converted to angiotensin II. Angiotensin in turn potentiates the vasoconstrictor responses to adrenergic stimuli presumably by augmenting release of the adrenergic transmitter and inhibiting its neuronal reuptake as well as by increasing vascular reactivity to norepinephrine.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 172259     DOI: 10.1161/01.res.38.1.26

Source DB:  PubMed          Journal:  Circ Res        ISSN: 0009-7330            Impact factor:   17.367


  25 in total

1.  A clinical pharmacological assessment of doxazosin and enalapril in combination.

Authors:  A D Bainbridge; P A Meredith; H L Elliott
Journal:  Br J Clin Pharmacol       Date:  1993-12       Impact factor: 4.335

2.  Chronic treatment of the spontaneously hypertensive rat with captopril attenuates responses to noradrenaline in vivo but not in vitro.

Authors:  J Atkinson; M Sonnay; M Sautel; A K Fouda
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1987-06       Impact factor: 3.000

3.  Probable involvement of vascular angiotensin II formation in the beta 2-adrenoceptor-mediated facilitation of the neurogenic vasopressor response in the pithed rat.

Authors:  E Schlicker; K Erkens; M Göthert
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1988-11       Impact factor: 3.000

4.  Local formation of angiotensin II in the rat aorta: effect of endothelium.

Authors:  C Eglème; F Cressier; J M Wood
Journal:  Br J Pharmacol       Date:  1990-06       Impact factor: 8.739

5.  Role of the endothelium on the facilitatory effects of angiotensin I and angiotensin II on noradrenergic transmission in the caudal artery of the rat.

Authors:  D F Story; J Ziogas
Journal:  Br J Pharmacol       Date:  1986-01       Impact factor: 8.739

Review 6.  Humoral and neurohormonal aspects of blood pressure regulation: focus on angiotensin.

Authors:  D Ganten; G Stock
Journal:  Klin Wochenschr       Date:  1978

7.  Differential effects of phosphoramidon on contractile responses to angiotensin II in rat blood vessels.

Authors:  L Chen; J R McNeill; T W Wilson; V Gopalakrishnan
Journal:  Br J Pharmacol       Date:  1995-04       Impact factor: 8.739

8.  The effects of hexane on rat myocardium: a morphometric and morphological study.

Authors:  B Maharaj; S M Khedun; M A Gregory; T Naicker
Journal:  Int J Exp Pathol       Date:  1993-04       Impact factor: 1.925

9.  Angiotensin II-noradrenergic interactions in renovascular hypertensive rats.

Authors:  J B Zimmerman; D Robertson; E K Jackson
Journal:  J Clin Invest       Date:  1987-08       Impact factor: 14.808

10.  Metabolism of vasoactive peptides by human endothelial cells in culture. Angiotensin I converting enzyme (kininase II) and angiotensinase.

Authors:  A R Johnson; E G Erdös
Journal:  J Clin Invest       Date:  1977-04       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.